Volume 381, Issue 9868, Pages 744-751 (March 2013) Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial Andrew Howman, MMath, Tracey L Chapman, Maria M Langdon, MSc, Caroline Ferguson, BSc, Dwomoa Adu, MD, Prof John Feehally, DM, Gillian J Gaskin, PhD, David RW Jayne, MD, Prof Donal O'Donoghue, MB, Michael Boulton-Jones, FRCP, Prof Peter W Mathieson, FRCP The Lancet Volume 381, Issue 9868, Pages 744-751 (March 2013) DOI: 10.1016/S0140-6736(12)61566-9 Copyright © 2013 Elsevier Ltd Terms and Conditions
Figure 1 Trial profile The Lancet 2013 381, 744-751DOI: (10.1016/S0140-6736(12)61566-9) Copyright © 2013 Elsevier Ltd Terms and Conditions
Figure 2 Kaplan-Meier analysis of further 20% decline in renal function Deaths were censored. GFR=glomerular filtration rate. The Lancet 2013 381, 744-751DOI: (10.1016/S0140-6736(12)61566-9) Copyright © 2013 Elsevier Ltd Terms and Conditions
Figure 3 Change in measured or calculated 24-h urinary protein Datapoints show mean change in 24-h urinary protein from baseline; error bars show 95% CI. The numbers of patients from whom readings were taken at each timepoint are presented; variation in numbers was due to dropout and missing readings at those timepoints. The Lancet 2013 381, 744-751DOI: (10.1016/S0140-6736(12)61566-9) Copyright © 2013 Elsevier Ltd Terms and Conditions